Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.90EUR
−95.47 MEUR
28.15 MEUR
114.26 M
About CYMABAY THERAPEUTICS INC
Sector
Industry
Headquarters
Newark
Website
Employees (FY)
101
Founded
1988
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than 120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of C0I is 29.80 EUR — it hasn't changed in the past 24 hours. Watch CYMABAY THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CYMABAY THERAPEUTICS INC stocks are traded under the ticker C0I.
CYMABAY THERAPEUTICS INC is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
C0I stock is 0% volatile and has beta coefficient of 1.13. Track CYMABAY THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is CYMABAY THERAPEUTICS INC there?
C0I earnings for the last quarter are −0.32 EUR per share, whereas the estimation was −0.28 EUR resulting in a −12.59% surprise. The estimated earnings for the next quarter are −0.33 EUR per share. See more details about CYMABAY THERAPEUTICS INC earnings.
CYMABAY THERAPEUTICS INC revenue for the last quarter amounts to 51.64 K EUR despite the estimated figure of 385.05 K EUR. In the next quarter revenue is expected to reach 0 EUR.
Yes, you can track CYMABAY THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
C0I net income for the last quarter is −37.96 M EUR, while the quarter before that showed −32.05 M EUR of net income which accounts for −18.44% change. Track more CYMABAY THERAPEUTICS INC financial stats to get the full picture.
No, C0I doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, C0I shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CYMABAY THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
As of May 10, 2024, the company has 101.00 employees. See our rating of the largest employees — is CYMABAY THERAPEUTICS INC on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CYMABAY THERAPEUTICS INC technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CYMABAY THERAPEUTICS INC stock shows the buy signal. See more of CYMABAY THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CYMABAY THERAPEUTICS INC future price: according to them, C0I price has a max estimate of 26.17 EUR and a min estimate of 18.69 EUR. Watch C0I chart and read a more detailed CYMABAY THERAPEUTICS INC stock forecast: see what analysts think of CYMABAY THERAPEUTICS INC and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CYMABAY THERAPEUTICS INC EBITDA is −91.51 M EUR, and current EBITDA margin is −325.03%. See more stats in CYMABAY THERAPEUTICS INC financial statements.